Two pilot investigations examined the hypothesis that MDI BEC administered in a tapering dosage schedule over the first 12 days of life reduces the incidence of BPD concomitant with modulation of BALF oxyradical inflammation. MDI BEC was dosed: 2 puffs QID × 3 days, then 2 puffs TID × 3 days, then 2 puffs BID × 3 days, then 2 puffs Q day × 3 days. Endotracheal tube aspirates were collected from mechanically ventilated premature infants on days 2, 4 and 6 of life. Biochemical variables assessed in endotracheal aspirates were normalized with respect of BALF urea dilution. In an initial group of 9 BEC-treated (777±113 g) and 9 historic controls (704±147 g) no differences in BALF total protein, lipid aldehydes or IL-8 could be demonstrated during the first week of life. BALF myeloperoxidase tended to be higher in controls on day 4 (p=0.075). BALF from control infants exhibited evidence of excess polyunsaturated fatty acid consumption on day 2 of life compared to BEC-treated infants. Significant differences were noted for% arachidonate (p=0.006), total polyunsaturated fatty acids (p=0.022), and ratio of polyunsaturated fatty acids to saturated fatty acids (p=0.027). Ratio of hydroxyl-linoleic acid to native linoleic acid tended to be higher in the control group on day 2 of life but was not statistically significant (p=0.158). For a subsequent group of 10 BEC-treated infants (903±203 g) and 10 control infants (834±205 g) a prospective, randomized, double blinded trial suggested that BEC-treated infants required fewer days of mechanical ventilation (31.9±16.6 vs 18.6±14.6, p=0.07). Need for O2 at 36 wks or home O2 also appeared to be lower in BEC-treated infants (55.6 vs 77.8% for both variables). Cosyntropin stimulation tests revealed no evidence of adrenal suppression in either group: cortisol levels pre/post cosyntropin (μg/dl) were: 6.9±4.2/20.8±8.4 and 9.7±6.5/21.0±9.6 for control and BEC-treated infants respectively. No other adverse effects of BEC were noted. MDI BEC in the dose utilized is safe, appears to reduce BALF oxyradical stress, and may have a beneficial clinical effect. Additional studies employing a higher dose of BEC and larger numbers of subjects are warranted.
(Supported by SCOR 1P50 HL46478, UW GCRC M01 PR03186, Thrasher Research Fund and Eleanor Naylor Dana Charitable Trust)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zimmerman, J., Kayata, S., Shivpuri, C. et al. Metered-Dose Inhaled (MDI) Beclomethasone (BEC) Initiated at Birth Attenuates Bronchoalveolar Lining Fluid (BALF) Oxyradical Stress in Premature Infants at Risk for Bronchopulmonary Dysplasia (BPD). ♦ 1631. Pediatr Res 41 (Suppl 4), 274 (1997). https://doi.org/10.1203/00006450-199704001-01650
Issue Date:
DOI: https://doi.org/10.1203/00006450-199704001-01650